GlassScriptPhysician profile
Tejas N Mehta
NPI 1518956143
$5,386.46
in general payments reported to CMS, 2019-2025
42 companies · $775 in 2025
The $775 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $806 · 2021: $688 · 2022: $416 · 2023: $802 · 2024: $438 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,321.36 | 2019-2025 | Aveir, Freestyle Libre 3, Cardiomems |
| Biotronik INC. | $462.13 | 2019-2025 | Amvia Edge, Acticor 7 Vr-T Dx, Biomonitor |
| Novo Nordisk INC | $433.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $417.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $397.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $219.70 | 2019-2025 | Airsupra |
| Amgen INC. | $204.15 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $185.03 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $174.89 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Abiomed | $145.65 | 2023 | Impella |
| Medtronic, INC. | $138.88 | 2021 | |
| Pfizer INC. | $126.90 | 2019-2025 | |
| Boston Scientific Corporation | $125.00 | 2019-2023 | Resonate El Icd Vr, Bodyguardian |
| Sanofi-Aventis U.S. LLC | $105.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.42 | 2019-2022 |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejas Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.